Changing perspectives in portal vein thrombosis

Area of Science:

• Hepatology
• Vascular Medicine
• Gastroenterology

Background:

• Portal vein thrombosis (PVT) etiology is complex, involving primary factors like cirrhosis, malignancies, and pancreatitis.
• Emerging risk factors include myeloproliferative disorders and genetic prothrombotic defects.
• A significant portion of PVT patients present with multiple coexisting thrombotic risk factors.

Purpose of the Study:

• To investigate the heterogeneous etiology of portal vein thrombosis (PVT).
• To analyze the clinical manifestations, prognosis, and mortality factors associated with PVT.
• To evaluate the efficacy of current therapeutic strategies for PVT and its complications.

Main Methods:

• Review of etiological factors contributing to PVT.
• Analysis of clinical presentation, focusing on variceal hemorrhage as a manifestation of portal hypertension.
• Evaluation of treatment outcomes for variceal bleeding and the role of anticoagulation.
• Multivariate survival analysis in a large Dutch PVT cohort.

Main Results:

• PVT does not typically impair liver function; variceal hemorrhage is a common manifestation with a better prognosis than in cirrhotic patients.
• Endoscopic treatments are primary for variceal bleeding; anticoagulation is reserved for specific acute cases or hypercoagulability.
• Mortality in PVT patients is primarily linked to underlying conditions (e.g., malignancy, ascites) and mesenteric vein thrombosis, not portal hypertension complications.

Conclusions:

• PVT's prognosis is largely determined by associated comorbidities rather than portal hypertension sequelae.
• Anticoagulant therapy's benefit in PVT is limited and case-specific.
• Further research is needed to clarify the survival benefit of surgical portosystemic shunting in PVT patients.